Literature DB >> 6993365

Salivary concentrations of amphotericin B following its use as an oral lozenge.

H G de Vries-Hospers, D van der Waaij.   

Abstract

Amphotericin B concentrations were measured in the saliva of ten healthy volunteers who had sucked on lozenges with this drug. It appeared that high amphotericin B concentrations can be achieved in this way in the saliva. Even half an hour after swallowing the last remnant of a lozenge, the amphotericin B concentration was found to be high enough to suppress the growth of sensitive Candida albicans strains. The possible usefulness of amphotericin B lozenges in the selective decontamination of the oropharynx of yeasts and other fungi is discussed and compared with the application of this drug in orabase.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6993365     DOI: 10.1007/bf01639148

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  18 in total

1.  Amphotericin B lozenges in the treatment of oral thrush.

Authors:  A Ewing
Journal:  Practitioner       Date:  1967-07

2.  Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. A prospective cooperative study of gnotobiotic care in acute leukemia patients. I: clinical results.

Authors:  M Dietrich; W Gaus; J Vossen; D van der Waaij; F Wendt
Journal:  Infection       Date:  1977       Impact factor: 3.553

3.  Fungaemia and funguria after oral administration of Candida albicans.

Authors:  W Krause; H Matheis; K Wulf
Journal:  Lancet       Date:  1969-03-22       Impact factor: 79.321

4.  Candidiasis: colonization vs infection.

Authors: 
Journal:  JAMA       Date:  1971-01-11       Impact factor: 56.272

Review 5.  The role of antibiotics in the pathogenesis of Candidainfections.

Authors:  M S Seelig
Journal:  Am J Med       Date:  1966-06       Impact factor: 4.965

Review 6.  Mechanisms by which antibiotics increase the incidence and severity of candidiasis and alter the immunological defenses.

Authors:  M S Seelig
Journal:  Bacteriol Rev       Date:  1966-06

7.  Infections in cancer patients on a protected environment-prophylactic antibiotic program.

Authors:  G P Bodey; V Rodriguez
Journal:  Am J Med       Date:  1975-10       Impact factor: 4.965

8.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

9.  Causes of death in adults with acute leukemia.

Authors:  H Y Chang; V Rodriguez; G Narboni; G P Bodey; M A Luna; E J Freireich
Journal:  Medicine (Baltimore)       Date:  1976-05       Impact factor: 1.889

10.  Amphotericin B concentrations in saliva after application of 2% amphotericin B in orabase.

Authors:  H G de Vries-Hospers; D van der Waaij
Journal:  Infection       Date:  1978       Impact factor: 3.553

View more
  3 in total

1.  Clinical use of selective decontamination: the concept.

Authors:  D van der Waaij; W L Manson; J P Arends; H G de Vries-Hospers
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

2.  The effect of amphotericin B lozenges on the presence and number of Candida cells in the oropharynx of neutropenic leukemia patients.

Authors:  H G de Vries-Hospers; N H Mulder; D T Sleijfer; H K van Saene
Journal:  Infection       Date:  1982       Impact factor: 3.553

3.  Salivary nystatin concentrations after administration of an osmotic controlled release tablet and a pastille.

Authors:  M Encarnacion; I Chin
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.